Project description
Innovative platform to support high-impact medicine-repurposing projects
The development of a new medicine is a lengthy and complex undertaking, and the risks are high as many projects fail during the development process. Exploring the potential use of existing medicines in areas of unmet medical needs is one alternative. In this context, the EU-funded REMEDI4ALL project aims to establish Europe's leadership globally in the repurposing of medicines by creating a vibrant community of practice. Bringing together all sectors and involving the right experts at the right time, REMEDI4ALL will create new connections to test and validate existing medicines for a new purpose. Four preclinical and clinical phase demonstrators in a variety of disease areas (including oncology, and rare and infectious diseases) will validate the tools and processes developed by the project.
Objective
REMEDI4ALL aims to establish Europe's leadership globally in the repurposing of medicines by creating a vibrant community of practice covering all relevant sectors and disciplines. REMEDI4ALL will establish and operate a permanent European research and innovation platform comprising the complete value chain for cutting edge, patient-focused repurposing, collaborating with users to execute high potential projects at any phase of development, upskilling all stakeholder groups through a comprehensive education and training portfolio, and advancing cross-sectoral policy dialogue with all relevant stakeholders and thought leaders. The tools and processes developed assembled in REMEDI4ALL will be validated in a portfolio of 4 ambitious preclinical and clinical phase demonstrators, representing high patient need in a variety of disease areas, including oncology, rare and infectious diseases.
The REMEDI4ALL platform will operate a complete, harmonised and accessible value chain integrating the scientific, methodological, financial, legal, regulatory, and intellectual property aspects of the repurposing approach in a goal-oriented and patient-centric approach. Working closely together with research funders and the patient community, REMEDI4ALL will engage and support a substantial user base and concomitant investments through a permanently sustainable entity, working closely with the permanent European Infrastructures and partners. The community of practice comprises leading academic and clinical facilities and infrastructures, medicines regulators, health technology assessors, public agencies and funders, small and large industry, state-of-the-art artificial intelligence and in silico tools, and a global network of collaborators for optimal knowledge exchange. REMEDI4ALL will substantially increase Europe's capacity to develop high quality repurposed medicines and implement them into market, through its complete value chain and consensus-based policy development mission.
Fields of science
Programme(s)
Funding Scheme
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinator
1081 HZ Amsterdam
Netherlands
See on map
Participants (20)
80686 Munchen
See on map
00014 Helsingin Yliopisto
See on map
75014 Paris
See on map
20156 Milano
See on map
80131 Napoli
See on map
75014 Paris
See on map
20122 Milano
See on map
2593 CE DEN HAAG
See on map
08007 Barcelona
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1050 Bruxelles / Brussel
See on map
1142 Budapest
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
17177 Stockholm
See on map
08003 Barcelona
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1860 Meise
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1000 Ljubljana
See on map
53175 Bonn
See on map
40136 Bologna
See on map
28046 MADRID
See on map
751 05 Uppsala
See on map
37075 Goettingen
See on map
Partners (3)
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
CB1 2BL Cambridge
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
S10 2TN Sheffield
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
HU6 7RX Hull
See on map